書籍詳細

特別講演1. 腸内細菌とリウマチ性疾患

P.33 掲載の参考文献

• 1) Nicholson JK, Holmes E, Kinross J et al.:Host-gut microbiota metabolic interaction. Science 2012, 336:1262-1267

• 2) Huttenhower C, Gevers D, Knight R et al.:Structure, function and diversity of the healthy human microbiome. Nature 2012, 486:207-214

• 3) Methe BA Nelson KE, Pop M et al.:A framework for human microbiome research. Nature 2012, 486:215-221

• 4) Cerf-Bensussan N, Gaboriau-Routhiau V:The immune system and the gut microbiota:friends or foes? Nature Rev/Immunol 2010, 10:735-744

• 5) Scher JU, Abramson SB:The microbiome and rheumatoid arthritis. Nat Rev Rheumatol 2011, 7:569-578

• 6) Clemente JC, Ursell LK, Parfrey LW et al.:The impact of the gut microbiota on human health:an integrative view. Cell 2012, 148:1258-1270

• 7) Hollander JL:Introduction to arthritis and rheumatic diseases. In:Arthritis and Allied conditions, 8th edn, (ed by Hollander JL, McCarty DJ, Jr. ), Lea & Febiger, Philadelphia, 1972, p3-14

• 8) Aoki S:Are enterobacterial common antigens involved in the etiology of rheumatoid arthritis? Clin Exp Rheumatol 2005, 23:285-288

• 9) Kunin CM, Beard MV, Halmagyi NE:Evidence for a common hapten associated with endotoxin fractions of E. coli and other Enteriobacteriaceae. Proc Soc Exp Biol Med 1962, 111:160-166

• 10) Aoki S, Yoshikawa K, Yokoyama T et al.:Role of enteric bacteria in the pathogenesis of rheumatoid arthritis:evidence for antibodies to enterobacterial common antigens in rheumatoid sera and synovial fluids. Ann Rheum Dis 1996, 55:363-369

• 11) Aoki S, Ikuta K, Aoyama G:Induction of chronic polyarthritis in rabbits. Nature 1972, 237:168-169

• 12) Aoki S:Rheumatoid arthritis and enteric bacteria. Jpn J Rheumatol 1999, 9:325-352

• 13) Abdollahi-Roodsaz S, Joosten LA, Koenders MI et al.:Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 2008, 118:205-216

• 14) Wu HJ, Ivanov II, Darce J et al.:Gut-residing segmented且lamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 2010, 32:815-827

• 15) Yoshitomi H, Sakaguchi N, Kobayashi K et al.:A role for fungal β-glucans and their receptor Dectin-1 in the induction of autoimmune arthritis in genetically susceptible mice. JEM 2005, 201:949-960

• 16) Taurog JD, Richardson JA, Croft JT et al.:The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med 1994, 180:2359-2364

• 17) Gardner DL:The experimental production of arthritis. A review. Ann Rheum Dis 1960, 19:297-317

• 18) Aoki S:Changes of medical terms in rheumatic disease. Rheumatol 2002, 27:266-272 (in Japanese)

• 19) Aoki S:Pathology in rheumatoid arthritis, In:New Illustrated Textbook of Orghopedic Surgery. Vol. 11 Rheumatoid Arthritis and Related Disorders, (ed by Inoue H, Kaneda K, Tomita K et al.), Medical View, Tokyo, 1994, p68-77 (in Japanese)

• 20) Aoki S, Ikuta K, Nonogaki T et al.:An immunopathologic study of rheumatoid factor in rheumatoid arthritis synovium by immunoperoxidase technique. Jpn J Rheumatol 1986, 1:17-23

• 21) Komatsu N, Tkayanagi H:Mechanism of inflammatory bone destruction. Nihon Rhinsho 2014, 72 (Suppl 3):116-120 (in Japanese)

• 22) Brasington RD, Jr.:Clinical features of rheumatoid arthritis. In:Rheumatology, Vol 1, 5th edn, (ed by Hochberg MC, Silman AJ, Smolen JS et al.), Mosby Elsevier, Philadelphia, 2011, p829-838

• 23) Abbas AK, Lichtman AH, Pillai S:Basic Immunology . Function and Disorders of the Immune System. 4th edn, Elsevier Saunders, Philadelphia, 2014, p71-91

• 24) Aoki S, Merkel M, McCabe WR:Immunofluorescent demonstration of the common enterobacterial antigen. Proc Soc Exp Biol Med 1966, 121:230-234

• 25) Aoki S, Aoki M, McCabe WR:Immuno且uorescent localization of bacterial antigen in pyelonephritis. I. The use of antisera against the common enterobacterial antigen in experimental renal lesions. J Lab Clin Med 1967, 70:204-212

• 26) Aoki S, Imamura S, Aoki M et al.:"ABACTERIAL" AND BACTERIAL PYELONPHRITIS. Immunofluorescent localization of bacterial antigen. N Engl J Med 1969, 281:1375-1382

• 27) Abruzzo JL, Christian CL:The induction of a rheumatoid factor-like substance in rabbits. J Exp Med 1961, 114:791-806

• 28) Aoki S:Animal models of rheumatoid arthritis. A review. J Chubu Rheum Ass 1990, 21:1-13

• 29) Aoki S:Experimental rheumatoid arthritis:Animal models of arthritis. In:Recent Advances in Immunopathology. (ed by Hamashima Y), Yamashiro Printing Co Ltd, Kyoto, 1987, p91-115

• 30) Aoki S:Experimental production of chronic polyarthritis by enterobacterial sensitization. In:Immunopathology of Rheumatic Fever and Rheumatoid Arthritis, (ed by Otaka Y), IGAKU SHOIN LTD, Tokyo, 1976, p260-275

• 31) Aoki S:Arthritic rabbits by sensitization with E coli. In:Experimental Animal Models of Intractable Diseases. (ed by Kyogoku M), Soft Science Co Ltd, Tokyo, 1984, p395-408 (in Japanese)

• 32) Aoki S:E coli-sensitized arthritis. In:Animal Models of Arthritis. (ed by Kyogoku M, Abe C), Ishiyaku Shuppan Co Ltd, Tokyo, 1985, p101-117 (in Japanese)

• 33) Aoki S, Ikuta K, Nonogaki T et al.:Induction of chronic polyarthritis in rabbits by hyperimmunization with Escherichia coli II. Immunohistologic findings in established arthritis. Jpn J Rheumatol 1997, 7:23-34

• 34) Aoki S:E coli-sensitized arthritis in rabbits. In:Arthritic Models. (ed by Abe C, Sawai T) Publisher Inc NIHON IGAKUKAN, Tokyo, 2000, p103-108 (in Japanese)

• 35) Hanglow AC, Welsh CJR, Conn P et al.:Experimental induction of rheumatoid factor and joint lesions in rabbits after intravenous injections of killed bacteria. Ann Rheum Dis 1986, 45:50-59

• 36) Aoki S, Ikuta K, Nonogaki T et al.:Induction of chronic polyarthritis in rabbits by hyperimmunization with Escherichia coli. I. Pathologic and serologic features in two breeds of rabbits. Arthritis Rheum 1985, 28:522-528

• 37) Okamoto R, Takagi T, Suzuku K et al.:Relationship between antibodies against E. coli O:14, and rheumatoid factor, ESR and CRP in rheumatoid arthritis (abstract). J Jpn Rheum Ass (Ryumachi) 1998, 38:316 (in Japanese)

• 38) Aoki S, Mitsui T, Yoshikawa K et al.:Experimental and clinical studies of enterobacterial sensitization in rheumatoid arthritis with special reference to changes of intestinal flora and influence of fasted therapy. J Chubu Rheum Ass 1999, 30:40-41 (in Japanese)

• 39) Kunin CM:Separation, characterization, and biological, significance of a common antigen in Enterobacteriaceae. J Exp Med 1963, 118:565-586

• 40) Hammarstrom S, Carlsson HE, Perlmann P et al.:Immunochemistry of the common antigen of Enterobacteriaceae (Kunin). Relation to lipopolysaccharide core structure. J Exp Med 1971, 134:565-576

• 41) Langer T, Lu C, Echols H et al.:Successive action of DnaK, DnaJ and GroEL along the pathway of chaperone-mediated protein folding. Nature 1992, 356:683-689

• 42) Lugtenberg B, van Alphen L:Molecular architecture and functioning of the outer membrane of Escherichia coli and other gram-negative bacteria. Biochim Biophys Acta 1983, 737:51-115

• 43) Kuhn H-M, Basu S, Mayer H:Comparison of enterobacterial common antigen from different species by serological teshniques. Eur J Biochim 1987, 162:69-74

• 44) Brentano F, Kyburz D, Gay S:Toll-like receptors and rheumatoid arthritis. In:Methods in Molecular Biology, Toll-Like Receptors. (ed by McCoy CE, O'Neill LAJ), vol 517, Humana Press, New Jersey, 2009, p329-343

• 45) Medzhitov R, Preston-Hurlburt P, Janeway CA Jr:A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388:394-397

• 46) Akira S:Innate Immunity:Recognition・Signals・Response. Japanese Center of Bifidobacterium, Tokyo, 2012, p3-29 (in Japanese)

• 47) Arend WP:The innate immune system in rheumatoid arthritis. Arthritis Rheum 2001, 44:2224-2234

• 48) Gierut A, Perlman H, Pope RM:Innate immunity and rheumatoid arthritis. Rheum Dis Clin North Am 2010, 36:271-296

• 49) Gregersen PK, Silver J, Winchester RJ:The shared epitope hypothesis. An apProach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987, 30:1205-1213

• 50) Albani S, Tuckwell JE, Esparza L et al.:The susceptibility sequence to rheumatoid arthritis is a cross-reactive B cell epitope shared by the Escherichia coli heat shock protein dnaJ and the histocompatibility leukocyte antigen DRB10401 molecule. J Clin Invest 1992, 89:327-331

• 51) Ebringer A, Ptaszynska T, Corbett M et al.:Antibodies to Proteus in rheumatoid arthritis. Lancet 1985, II:305-307

• 52) Wilson C, Tiwana H, Ebringer A:Molecular mimicry between HLA-DR alleles associated with rheumatoid arthritis and Proteus mirabilis as the aetiological basis for autoimmunity. Microb Infect 2000, 2:1489-1496

• 53) Schwimmbeck PL, Yu DTY, Oldstone MBA:Autoantibodies to HLA-B27 in the sera of HLA-B27 patients with ankylosing spondylitis and Reiter's syndrome. Molecular mimicry with Klebsiella pneumoniae as potential mechanism of autoimmune disease. J Esp Med 1987, 166:173-181

• 54) Rashid T, Ebringer A:Ankylosing spondylitis is linked to Klebsiella-the evidence. Clin Rheumatol 2007, 26:858-864

• 55) Harris ED Jr:Rheumatoid Arthritis. WB Saunders Co, Philadelphia, 1997, p41-51

• 56) Aoki S, Mitsui T:Histological features of rheumatoid arthritis patients having antibodies to enterobacterial common antigens:Correlation of antibody levels with semiquantitative histologic scores and laboratory markers. Clin Exp Rheumatol 2005, 23:13-18
  pubmed

• 57) Ebringer A, Wilson C, Tiwana H:Is rheumatoid arthritis a form of reactive arthritis? J Rheumatol 2000, 27:559-563

• 58) Benno Y:The whole aspect of intestinal且ora made known and elucidation of the function. Infect Dis 2007, 37:1-8 (in Japanese)

• 59) Hattori M:Microbiome producing an individual difference. Nikkei Science 2012, 10:50-57 (in Japanese)

• 60) Olhagen B, Mansson I:Intestinal Clostridium perfringens in rheumatoid arthritis and other collagen diseases. Acta Med Scand 1968, 184:395-402

• 61) Shinebaum R, Neumann VC, Cooke EM et al.:Comparison of faecal florae in patients with rheumatoid arthritis and controls. Brit J Rheumatol 1987, 26:329-333

• 62) Eerola E, Mottonen T, Hannonen P et al.:Intestinal且ora in early rheumatoid arthritis. Brit J Rheumatol 1994, 33:1030-1038

• 63) Vaahtovuo J, Munukka E, Korkeamaki M et al.:Fecal microbiota in early rheumatoid arthritis. J Rheumatol 2008, 35:1500-1505

• 64) Scher JU, Sczesnak A, Longman RS et al.:Expansion of intestinal Prevotella copri correlates with enhanced susceptibility to arthritis. eLife 2013, 2:e01202
  pubmed

• 65) Honda K, Littman DR:The microbiome in infectious disease and inflammation. Annu Rev Immunol 2012, 30:759-795

• 66) Sartor RB:Role of the enteric microflora in pathogenesis of intestinal infiammation and arthritis. Aliment Pharmacol Ther 1997, 11 (Suppl 3):17-23

• 67) Salmi M, Andrew DP, Butcher EC et al.:Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans:dissection of the molecular mechanisms. J Exp Med 1995, 181:137-149

• 68) Hollander JL, McCarty DJ Jr, Astorga G et al.:Studies on the pathogenesis of rheumatoid joint inflammation. I. The "R. A. Cell" and a working hypothesis. Ann Intern Med 1965, 62:271-280

• 69) Mclnnes IB, Schett G:The pathgenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219

• 70) Feldmann M, Maini RN:Anti-TNFα therapy of rheumatoid arthritis:what have we learned? Annu Rev Immunol 2001, 19:163-196

• 71) Ishiguro N:Progress in therapy for rheumatoid arthritis. Modern Med 2009, 57:41-45 (in Japanese)

• 72) Keffer J, Probert L, Cazlaris H et al.:Transgenic mice expressing human tumour necrosis factor:a predictive genetic model of arthritis. EMBOJ 1991, 10:4025-4031

• 73) Scott DL, Kingsley GH:Tumor necrosis factor inhibitors for rheumatoid arthritis. N Engl J Med 2006, 355:704-712

• 74) Palmblad J, Hafstrom I, Ringertz B:Antirheumatic effects of fasting. Rheum Dis Clin North Am 1991, 17:351-362

• 75) Longo VD, Mattson MP:Fasting:molecular mechnisms and clinical applications. Cell Metabolism 2014, 19:181-192

• 76) Kjeldsen-Kragh J, Haugen M, Brochgrevink CF et al.:Controlled trial of fasting and one-year vegetarian diet in rheumatoid arthritis. Lancet 1991, 338:899-902

• 77) Lomax AR, Calder PC:Probiotics, immune function, infection and inflammation:a review of the evidence from studies conducted in humans. Curr Pharmaceuti design 2009, 15:1428-1518

• 78) Fooks LJ, Gibson GR:Probiotics as modulators of the gut flora. J Nutrition 2002, 88 (Suppl 1):S39-S49

• 79) Vaarala O:Immunological effects of probiotics with special reference to lactobacilli. Clin Exp Allergy 2003, 33:1634-1640

• 80) Kaminogawa S:Probiotics-its present state and prospect. Infect Dis 2003, 33:95-100 (in Japanese)

• 81) Honda K:Intestinal commensal microbiota and mucosal immune system. SAISHIN IGAKU 2013, 68:543-551 (in Japanese)

• 82) Losenfeldt V, Benfeldt E, Valerius HN et al:Effect of probiotics on gastrointestinal symptoms and small intestinal permeability in children with atopic dermatitis. J Pediatr 2004, 145:612-616

• 83) Amdekar S, Singh V, Singh R:Lactobacillus casei reduces the inflammatory joint damage associated with collagen-induced arthritis (CIA) by reducing the pro-inflammatory cytokines. J Clin Immunol 2011, 31:147-154

• 84) Hatakka K, Martio J, Korpela M et al.:Effects of probiotic therapy on the activity and activation of mild rheumatoid arthritis. Sand J Rheumatol 2003, 32:211-215

• 85) Mandel DR, Eichas K, Holmes J:Bacillus coagulans:a viable adjunct therapy for relieving symptoms of rheumatoid arthritis according to a randomized, controlled trial. BMC Complementary & Alternative Med 2010, 10:1-7

• 86) Pineda Mde L, Thompson SF, Summers K et al.:A randomized, double-blinded, placebo-controlled pilot study of probiotics in active rheumatoid arthritis. Med Sci Monit 2011, 17:CR347-354

• 87) Vaghef-Mehrabany E, Alipour B, Homayouni-Rad A et al.:Probiotic supplementation improves inflammatory status in patients with rheumatoid arthritis. Nutrition 2014, 30:430-435

• 88) Alipour B, Homayouni-Rad A, Vaghef-Mehrabany E et al.:Effect of Lactobacillus casei supplementation on disease activity and inflammatory cytokines in rheumatoid arthritis patients:a randomized double-blind clinical trial. Int J Rheuni Dis 2014:1-9

• 89) Okamoto R, Saito T, Mochida Y et al.:Effectiveness of probiotics (Beverage containing Lactobacillus casei strain Shirota) against the patient's condition of rheumatoid arthritis. Abstract submitted for the 56th Annual General Assembly and Scientific Meeting of the Japan College of Rheumatolory, Tokyo, 2012:507 (in Japanese)

• 90) Peltonen R, Nenonen M, Helve T et al.:Fecal microbial flora and disease activity in rheumatoid arthritis during a vegan diet. Brit J Rheumatol 1997, 36:64-68

• 91) Spanhaak S, Havenaar R, Schaafsma G:The effect of consumption of milk fermented by Lactobacillus casei strain Shirota on the intestinal microflora and immune parameters in humans. Eur J Clin Nutrition 1998, 52:899-907

• 92) Nenonen MT, Helve TA, Rauma A-L et al.:Uncooked, lactobacilli-rich, vegan food and rheumatoid arthritis. Brit J Rheumatol 1998, 37:274-281

特別講演2. 粘膜バリアにおける免疫システム - 腸内細菌のクロストーク

P.42 掲載の参考文献

• 1) R. E. Ley, D. A. Peterson, J. I. Gordon:Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell 2006, 124:837-848

• 2) J. J. Cebra, S. B. Periwal, G. Lee, F. Lee, K. E. Shroff:Development and maintenance of the gut-associated lymphoid tissue (galt):the roles of enteric bacteria and viruses. Dev Immunol 1998, 6:13-18

• 3) L. M. Kato, S. Kawamoto, M. Maruya, S. Fagarasan:The role of the adaptive immune system in regulation of the gut microbiota. Immunol Rev 2014, 260:67-75

• 4) S. Kawamoto et al.:Foxp3+ T cells regulate immunoglobulin a selection and facilitate diversification of bacterial species responsible for immue homeostasis. Immunity, 2014, 41:152-165

• 5) S. Fagarasan, T. Honjo:Intestinal IgA synthesis:regulation of front-line body defences. Nat Rev Immunol 2003, 3:63-72

• 6) R. A. Strugnell, O. L. Wijburg:The role of secretory antibodies in infection immunity. Nat Rev Microbiol 2010, 8:656-667

• 7) L. A. van der Waaij, P. C. Limburg, G. Mesander, D. van der Waaij:In vivo IgA coating of anaerobic bacteria in human faces. Gut 1996, 38:348-354

• 8) S. Kawamoto et al.:The inhibitory receptor PD-1 regulates IgA selection and bacterial composition in the gut. Science 2012, 336:485-489

• 9) S. Fagarasan et al.:Critical roles of activation-induced cytidine deaminase in the homeostasis of gut flora. Science 2002, 298:1424-1427

• 10) M. Muramatsu et al.:Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), apotential RNA editing enzyme. Cell 2000, 102:553-563

• 11) K. Suzuki et al.:Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut. Proc Natl Acad Sci USA 2004, 101:1981-1986

• 12) N. Shulzhenko et al.:Crosstalk between B lymphocytes, microbiota and the intestinal epithelium governs immunity versus metabolism in the gut. Nat Med 2011, 17:1585-1593

• 13) M. Wei et al.:Mice carrying a knock-in mutation of Aicda resulting in a defect in somatic hypermutation have impaired gut homeostasis and compromised mucosal defense. Nat Immunol 2011, 12:264-270

• 14) L. M. Kato, S. Kawamoto, M. Maruya, S. Fagarasan:Gut TFH and IgA:key players for regulation of bacterial communities and immune homeostasis. Immunol Cell Biol 2013, 92:49-56

• 15) T. Okazaki, S. Chikuma, Y. Iwai, S. Fagarasan, T. Honjo:A rheostat for immune responses:the unique proerties of PD-1 and their advantages for clinical application. Nat Immunol 2013, 14:1212-1218

• 16) M. Tsuji et al.:Preferentinal generation of follicular B helper T cells from Foxp3+ T cells in gut peyer's patches. Science 2009, 323:1488-1492

• 17) K. Atarashi et al.:Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011, 331:337-341

• 18) Y. Cong, T. Feng, K. Fujihashi, T. R. Schoeb, C. O. Elson:A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci USA 2009, 106:19256-19261

• 19) N. Wang et al.:Selective IgA deficiency in autoimmune diseases. Mol Med 2011, 17:1383-1396

• 20) D. B. Sutherland, S. Fagarasan:IgA synthesis:a form of functional immune adaptation extending beyond gut. Curr Opin Immunol 2012, 24:261-268

講演1. 腸内細菌叢と関節破壊

P.46 掲載の参考文献

• 1) Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, Heuvelmans-Jacobs M, Akira S, Nicklin MJ, Ribeiro-Dias F, van den Berg WB:Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest. 2008, 118 (1):205-216

• 2) Abdollahi-Roodsaz S, Joosten LA, Helsen MM, Walgreen B, van Lent PL, van den Bersselaar LA, Koenders MI, van den Berg WB:Shift from TLR2 toward TLR4 dependency in the erosive stage of chronic SCW arthritis coincides with TLR4 mediated IL-17 production. Arthritis Rheum. 2008,58（12）：3753-3764

• 3) Koenders MI, Marijnissen RJ, Joosten LA, Abdollahi-Roodsaz S, Di Padova FE, van de Loo FA, Dulos J, van den Berg WB, Boots AM:T cell lessons from the RA synovium SCID mouse model. Arthritis Rheum. 2012, 64 (6):1762-1770

• 4) de Aquino SG, Abdollahi-Roodsaz S, Koenders MI, van de Loo FA, Pruijn GJ, Marijnissen RJ, Walgreen B, Helsen MM, van den Bersselaar LA, de Molon RS, Avila Campos MJ, Cunha FQ, Cirelli JA, van den Berg WB:Peridontal pathogens directly promote autoimmune experimental arthritis by inducing TLR2 and IL-1 driven Th17 responses. J Immunol. 2014, 192 (9):4103

講演2. 腸内細菌と1型糖尿病

P.51 掲載の参考文献

• 1) Chervonsky, A. V.:Microbiota and autoimmunity. Cold Spring Harbor perspectives in biology 2013, 5:a007294, doi:10.1101/cshperspect. a007294

• 2) Chervonsky, A. V.:Influence of microbial environment on autoimmunity. Nat Immunol 2010, 11:28-35, doi:ni.1801 [pii] 10.1038/ni.1801

• 3) Wen, L. et al.:Innate immunity and intestinal microbiota in the development of Type 1 diabetes. Nature 2008, 455:1109-1113, doi:nature07336 [pii] 10.1038/nature07336

講演3 腸内フローラと炎症性腸疾患

P.58 掲載の参考文献

• 1) Coombes JL, Powrie F:Dendritic cells in intestinal immune regulation. Nat Rev Immunol 2008, 8:435-446

• 2) Steinman RM, Hawiger D, Nussenzweig MC:Tolerogenic dendritic cells. Annu Rev Immunol 2003, 21:685-711

• 3) Strober W, Fuss I, Mannon P:The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521

• 4) Xavier RJ, Podolsky DK:Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434

• 5) Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Consortium NIG, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Belgian-French IBDC, Wellcome Trust Case Control C, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ:Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955-962

• 6) Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH:A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463

• 7) Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, Nimmo ER, Massey D, Berzuini C, Johnson C, Barrett JC, Cummings FR, Drummond H, Lees CW, Onnie CM, Hanson CE, Blaszczyk K, Inouye M, Ewels P, Ravindrarajah R, Keniry A, Hunt S, Carter M, Watkins N, Ouwehand W, Lewis CM, Cardon L, Wellcome Trust Case Control C, Lobo A, Forbes A, Sanderson J, Jewell DP, Mansfield JC, Deloukas P, Mathew CG, Parkes M, Satsangi J:Genetic determinants of ulcerative colitis include the ECMI locus and five loci implicated in Crohn's disease. Nat Genet 2008, 40:710-712

• 8) Hugot Jp, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J, Almer S, Tysk C, OMorain CA, Gassull M, Binder V, Finkel Y, Cortot A, Modigliani R, Laurent-Puig P, Gower-Rousseau C, Macry J, Colombel JF, Sahbatou M, Thomas G:Association of NOD21eucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001, 411:599-603

• 9) Khor B, Gardet A, Xavier RJ:Genetics and pathogenesis of inflammatory bowel disease. Nature 2011, 474:307-317

• 10) Kobayashi T, Okamoto S, Hisamatsu T, Kamada N, Chinen H, Saito R, Kitazume MT, Nakazawa A, Sugita A, Koganei K, Isobe K, Hibi T:IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut 2008, 57:1682-1689

• 11) Neurath MF:IL-23:a master regulator in Crohn disease. Nat Med 2007, 13:26-28

• 12) Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar Jp, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nunez G, Cho JH:A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411:603-606

• 13) Yen D, Cheung J, Scheerens H, Poulet F, McClanahan T, McKenzie B, Kleinschek MA, Owyang A, Mattson J, Blumenschein W, Murphy E, Sathe M, Cua DJ, Kastelein RA, Rennick D:IL-23 is essential for T cellmediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310-1316

• 14) Kayama H, Takeda K:Regulation of intestinal homeostasis by innate and adaptive immunity. Int Immunol 2012, 24:673-680

• 15) Bogunovic M, Ginhoux F, Helft J, Shang L, Hashimoto D, Greter M, Liu K, Jakubzick C, Ingersoll MA, Leboeuf M, Stanley ER, Nussenzweig M, Lira SA, Randolph GJ, Merad M:Origin of the lamina propria dendritic cell network. Immunity 2009, 31:513-525

• 16) Schulz O, Jaensson E, Persson EK, Liu X, Worbs T, Agace WW, Pabst O:Intestinal CD103+, but not CX3CR1+, antigen sampling cells migrate in lymph and serve classical dendritic cell functions. J Exp Med 2009, 206:3101-3114
  pubmed

• 17) Varol C, Vallon-Eberhard A, Elinav E, Aychek T, Shapira Y, Luche H, Fehling HJ, Hardt WD, Shakhar G, Jung S:Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity 2009, 31:502-512

• 18) Farache J, Koren I, Milo I, Gurevich I, Kim KW, Zigmond E, Furtado GC, Lira SA, Shakhar G:Luminal bacteria recruit CD103+ dendritic cells into the intestinal epithelium to sample bacterial antigens for presentation. Immunity 2013, 38:581-595

• 19) Jaensson E, Uronen-Hansson H, Pabst O, Eksteen B, Tian J, Coombes JL, Berg PL, Davidsson T, Powrie F, Johansson-Lindborn B, Agace WW:Small intestinal CD103+ dendritic cells display unique functional properties that are conserved between mice and humans. J Exp Med 2008, 205:2139-2149

• 20) Johansson-Lindbom B, Svensson M, Pabst O, Palmqvist C, Marquez G, Forster R, Agace WW:Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Eep Med 2005, 202:1063-1073

• 21) McDole JR, Wheeler LW, McDonald KG, Wang B, Konjufca V, Knoop KA, Newberry RD, Miller MJ:Goblet cells deliver luminal antigen to CD103+ dendritic cells in the small intestine. Nature 2012, 483:345-349

• 22) Sun CM, Hall JA, Blank RB, Bouladoux N, Oukka M, Mora JR, Belkaid Y:Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J Exp Med 2007, 204:1775-1785

• 23) Weber B, Saurer L, Schenk M, Dickgreber N, Mueller C:CX3CR1 defines functionally distinct intestinal mononuclear phagocyte subsets which maintain their respective functions during homeostatic and inflammatory conditions. Eur J Immunol 2011, 41:773-779

• 24) Atarashi K, Nishimura J, Shima T, Umesaki Y, Yamamoto M, Onoue M, Yagita H, Ishii N, Evans R, Honda K, Takeda K:ATP drives lamina propria TH17 cell differentiation. Nature 2008, 455:808-812

• 25) Bain CC, Scott CL, Uronen-Hansson H, Gudjonsson S, Jansson O, Grip O, Guilliams M, Malissen B, Agace WW, Mowat AM:Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol 2013, 6:498-510

• 26) Denning TL, Wang YC, Patel SR, Williams IR, Pulendran B:Lamina propria macrophages and dendritic cells differentially induce regulatory and interleukin 17-producing T cell responses. Nat Immunol 2007, 8:1086-1094

• 27) Rivollier A, He J, Kole A, Valatas V, Kelsall BL:Inflammation switches the differentiation program of Ly6Chi monocytes from antiinflammatory macrophages to inflammatory dendritic cells in the colon. J Exp Med 2012, 209:139-155

• 28) Zigmond E, Varol C, Farache J, Elmaliah E, Satpathy AT, Friedlander G, Mack M, Shpigel N, Boneca IG, Murphy KM, Shakhar G, Halpern Z, Jung S:Ly6Chi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity 2012, 37:1076-1090

• 29) Hadis U, Wahl B, Schulz O, Hardtke-Wolenski M, Schippers A, Wagner N, Muller W, Sparwasser T, Forster R, Pabst O:Intestinal tolerance requires gut homing and expansion of FoxP3＋regulatory T cells in the lamina propria. Immunity 2011, 34:237-246

• 30) Kayama H, Ueda Y, Sawa Y, Jeon SG, Ma JS, Okumura R, Kubo A, Ishii M, Okazaki T, Murakami M, Yamamoto M, Yagita H, Takeda K:Intestinal CX3C chemokine receptor 1high (CX3CR1high) myeloid cells prevent T-cell-dependent colitis. Proc Natl Acad Sci USA 2012, 109:5010-5015

• 31) Smith PD, Smythies LE, Mosteller-Barnum M, Sibley DA, Russell MW, Merger M, Sellers MT, Orenstein JM, Shimada T, Graham MF, Kubagawa H:Intestinal macrophages lack CD14 and CD89 and consequently are down-regulated for LPS-and IgA-mediated activities. J Immunol 2001, 167:2651-2656

• 32) Smythies LE, Sellers M, Clements RH, Mosteller-Barnum M, Meng G, Benjamin WH, Orenstein JM, Smith PD:Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005, 115:66-75

• 33) Kamada N, Hisamatsu T, Honda H, Kobayashi T, Chinen H, Kitazume MT, Takayama T, Okamoto S, Koganei K, Sugita A, Kanai T, Hibi T:Human CD14+ macrophages in intestinal lamina propria exhibit potent antigen-presenting ability. J Immunol 2009, 183:1724-1731

• 34) Kamada N, Hisamatsu T, Okamoto S, Chinen H, Kobayashi T, Sato T, Sakuraba A, Kitazume MT, Sugita A, Koganei K, Akagawa KS, Hibi T:Unique CD14 intestinal macrophages contribute to the pathogenesis of Crohn disease via IL-23/IFN-gamma axis. J Clin Invest 2008, 118:2269-2280

• 35) Schlitzer A, McGovern N, Teo P, Zelante T, Atarashi K, Low D, Ho AW, See P, Shin A, Wasan PS, Hoeffel G, Malleret B, Heiseke A, Chew S, Jardine L, Purvis HA, Hilkens CM, Tam J, Poidinger M, Stanley ER, Krug AB, Renia L, Sivasankar B, Ng LG, Collin M, Ricciardi-Castagnoli P, Honda K, Haniffa M, Ginhoux F:IRF4 transcription factor-dependent CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine responses. Immunity 2013, 38:970-983

• 36) Watchmaker PB, Lahl K, Lee M, Baumjohann D, Morton J, Kim SJ, Zeng R, Dent A, Ansel KM, Diamond B, Hadeiba H, Butcher EC:Comparative transcriptional and functional profiling defines conserved programs of intestinal DC differentiation in humans and mice. Nat Immunol 2014, 15:98-108

• 37) Ogino T, Nishimura J, Barman S, Kayama H, Uematsu S, Okuzaki D, Osawa H, Haraguchi N, Uemura M, Hata T, Takemasa I, Mizushima T, Yamamoto H, Takeda K, Doki Y, Mori M:Increased Th17-inducing activity of CD14+ CD163 low myeloid cells in intestinal lamina propria of patients with Crohn's disease. Gastroenterology 2013, 145:1380-1391 e1381

講演4. 腸内細菌叢と多発性硬化症

P.65 掲載の参考文献

• 1) Yamamura T, Miyake S:Diet, gut flora and multiple sclerosis:current research and future perspectives. Multiple Sclerosis Immunology (edited by Yamamura T & Gran B), Springer, 2013 (in press)

• 2) Sawcer S et al.:Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011, 476:214-219

• 3) Houzen H et al.:Increasing Prevalence and incidence of multiple sclerosis in northern Japan. MSJ 2008, 14:887-892

• 4) Ascherio A, Munger KL:Environmental risk factors for multiple sclerosis. Part II:noninfectious factors. Ann Neurol 2007, 61:504-513

• 5) 山村隆:多発性硬化症と環境因子. Current Insights in Neurological Science. 2006, 14:10-11

• 6) Yokote H et al.:NKT cell-dependent amelioration of a mouse model of multiple sclerosis by altering gut flora. Am J Pathol 2008, 173:1714-1723

• 7) Ochoa-Reparaz J et al.:Role of gut commensal microflora in the development of experimental autoimmune encephalomyelitis. J Immunol 2009, 183:6041-6050

• 8) Lee YK et al.:Proinflammatory T-cell responses to gut microbiota promote experimental autoimmune encephalomyelitis. PNAS 2011, 108:4615-4622

• 9) Berer K et al.:Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 2011, 479:538-541

• 10) Yamamura T:Interrogating innate immunity and key environmental interactions. Keystone Symposium, Multiple Sclerosis, Montana, USA, 1. 13, 2013

• 11) Kahn SA et al.:Fecal bacteriotherapy for ulcerative colitis:patients are ready, are we? Inflamm Bowel Dis 2012, 18:676-684

• 12) Maslowski K, Mackay CR:Diet, gut microbiota and immune responses. Nat Immunol 2011, 12:5-9

講演5. 炎症関連大腸がんモデルにおける大腸粘膜付随細菌叢の破綻

P.73 掲載の参考文献

• 1) Umesaki, Y., Y. Okada, S. Matsumoto, A. Imaoka, and H. Setoyama:Segmented filamentous bacteria are indigenous intestinal bacteria that activate intraepithelial lymphocytes and induce MHC class II molecules and fucosyl asialo GMI glycolipids on the small intestinal epithelial cells in the ex-germ-free mouse. Microbiol Immunol 1995, 39:555-562

• 2) Umesaki, Y., H. Setoyama, S. Matsumoto, A. Imaoka, and K. Itoh:Differential roles of segmented filamentous bacteria and clostridia in development of the intestinal immune system. Infect Immun 1999, 67:3504-3511

• 3) Atarashi, K., T. Tanoue, T. Shima, A. Imaoka, T. Kuwahara, Y. Momose, G. Cheng, S. Yamasaki, T. Saito, Y. Ohba, T. Taniguchi, K. Takeda, S. Hori, Ivanov, II, Y. Umesaki, K. Itoh, and K. Honda:Induction of colonic regulatory T cells by indigenous Clostridium species. Science 2011, 331:337-341

• 4) Wei, M., R. Shinkura, Y. Doi, M. Maruya, S. Fagarasan, and T. Honjo:Mice carrying a knock-in mutation of Aicda resulting in a defect in somatic hypermutation have impaired gut homeostasis and compromised mucosal defense. Nat Immunol 2011, 12:264-270

• 5) Matsumoto, S., Y. Okabe, H. Setoyama, K. Takayama, J. Ohtsuka, H. Funahashi, A. Imaoka, Y. Okada, and Y. Umesaki:Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998, 43:71-78

• 6) Maharshak, N., C. D. Packey, M. Ellermann, S. Manick, J. P. Siddle, E. Y. Huh, S. Plevy, R. B. Sartor, and I. M. Carroll:Altered enteric microbiota ecology in interleukin 10-deficient mice during development and progression of intestinal inflammation. Gut Microbes 2013, 4:316-324

• 7) Matsumoto, S., T. Hara, K. Mitsuyama, M. Yamamoto, O. Tsuruta, M. Sata, J. Scheller, S. Rose-John, S. Kado, and T. Takada:Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 2010, 184:1543-1551

• 8) Rhodes, J. M. , and B. J. Campbell:Inflammation and colorectal cancer:IBD-associated and sporadic cancer compared. Trends Mol Med 2002, 8:10-16

• 9) Koh, S. J., J. M. Kim, I. K. Kim, S. H. Ko, and J. S. Kim:Anti-inflammatory mechanism of metformin and its effects in intestinal inflammation and colitis-associated colon cancer. J Gastroenterol Hepatol 2014, 29:502-510.

• 10) Xiao, H., M. F. Gulen, J. Qin, J. Yao, K. Bulek, D. Kish, C. Z. Altuntas, D. Wald, C. Ma, H. Zhou, V. K. Tuohy, R. L. Fairchild, C. de la Motte, D. Cua, B. A. Vallance, and X. Li:The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 2007, 26:461-475

• 11) Shattuck-Brandt, R. L., G. W. Varilek, A. Radhika, F. Yang, M. K. Washington, and R. N. DuBois:Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10-/-mice. Gastroenterology 2000, 118:337-345

• 12) Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF:TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 2004, 21:491-501

• 13) Bollrath J, Greten FR:IKK/NF-kappaB and STAT3 pathways:central signaling hubs in inflammation-mediated tumour promotion and metastasis. EMBO Rep 2009, 10:1314-1319

• 14) LepPkes M, Becker C, Ivanov II, Hirth S, Wirtz S, Neufert C, Pouly S, Murphy AJ, Valenzuela DM, Yancopoulos GD, Becher B, Littman DR, Neurath MF:RORgamma-expressing Thl7 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009, 136:257-267

• 15) Balkwill F.:Tumour necrosis factor and cancer. Nat Rev Cancer 2009, 9:361-371

• 16) Kim BG, Li C, Qiao W, Mamura M, Kasprzak B, Anver M, Wolfraim L, Hong S, Mushinski E, Potter M, Kim SJ, Fu XY, Deng C, Letterio JJ:Smad4 signaling in T cells is required for supPression of gastrointestinal cancer. Nature 2006, 441:1015-1019

• 17) Bierie B, Moses HL:Transforming growth factor beta (TGF-β) and inflammation in cancer. Cytokine Growth Factor Rev 2010, 21:49-59

• 18) Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA, Oft M:IL-23 promotes tumour incidence and growth. Nature 2006, 442:461-465

• 19) Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA:Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008, 29:947-957

• 20) Suzuki, A., T. Hanada, K. Mitsuyama, T. Yoshida, S. Kamizono, T. Hoshino, M. Kubo, A. Yamashita, M. Okabe, K. Takeda, S. Akira, S. Matsumoto, A. Toyonaga, M. Sata, and A. Yoshimura:CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 2001, 193:471-481

• 21) Mitsuyama, K. , S. Matsumoto, S. Rose-John, A. Suzuki, T. Hara, N. Tomiyasu, K. Handa, O. Tsuruta, H. Funabashi, J. Scheller, A. Toyonaga, and M. Sata:STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut 2006, 55:1263-1269

• 22) Rose-John, S., and M. F. Neurath:IL-6 trans-signaling:the heat is on. Immunity 2004, 20:2-4

• 23) Wu, N., X. Yang, R. Zhang, J. Li, X. Xiao, Y. Hu, Y. Chen, F. Yang, N. Lu, Z. Wang, C. Luan, Y. Liu, B. Wang, C. Xiang, Y. Wang, F. Zhao, G. F. Gao, S. Wang, L. Li, H. Zhang, and B. Zhu:Dysbiosis signature of fecal microbiota in colorectal cancer patients. Microb Ecol 2013, 66:462-470

• 24) Keku, T. O., S. Dulal, A. Deveaux, B. Jovov, and X. Han:The gastrointestinal microbiota and colorectal cancer. Am J Physiol Gastrointest Liver Physiol 2012, 308:G351-G363

• 25) Ray, K.:Colorectal cancer:Fusobacterium nucleatum found in colon cancer tissue could an infection cause colorectal cancer? Nat Rev Gastroenterol Hepatol 2011, 8:662
  pubmed

• 26) Brynskov, J., P. Foegh, G. Pedersen, C. Ellervik, T. Kirkegaard, A. Bingham, and T. Saermark:Tumour necrosis factor α converting enzyme (TACE) activity in the colonic mucosa of patients with inflammatory bowel disease. Gut 2002, 51:37-43

• 27) Gomez MI, Sokol SH, Muir AB, Soong G, Bastien J, Prince AS:Bacterial induction of TNF-α converting enzyme expression and IL-6 receptorαshedding regulates airway infiammatory signaling. J Immunol. 2005, 175:1930-1936

• 28) van Passel, M. W., R. Kant, E. G. Zoetendal, C. M. Plugge, M. Derrien, S. A. Malfatti, P. S. Chain, T. Woyke, A. Palva, W. M. de Vos, and H. Smidt:The genome of Akkermansia muciniphila, a dedicated intestinal mucin degrader, and its use in exploring intestinal metagenomes. PLoS One 2011, 6:e16876.

• 29) Everard, A., C. Belzer, L. Geurts, J. P. Ouwerkerk, C. Druart, L. B. Bindels, Y. Guiot, M. Derrien, G. G. Muccioli, N. M. Delzenne, W. M. de Vos, and P. D. Cani:Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl Acad Sci USA 2013, 110:9066-9071

• 30) van der Waaij, L. A., F. G. Kroese, A. Visser, G. F. Nelis, B. D. Westerveld, P. L. Jansen, and J. O. Hunter:Immunoglobulin coating of faecal bacteria in inflammatory bowel disease. Eur J Gastroenterol Hepatol 2004, 16:669-674

• 31) Kawamoto, S., M. Maruya, L. M. Kato, W. Suda, K. Atarashi, Y. Doi, Y. Tsutsui, H. Qin, K. Honda, T. Okada, M. Hattori, and S. Fagarasan:Foxp3+ T cells regulate immunoglobulin a selection and facilitate diversification of bacterial species responsible for immune homeostasis. Inimunitv 2014, 41:152-165

• 32) Palm, N. W., M. R. de Zoete, T. W. Cullen, N. A. Barry, J. Stefanowski, L. Hao, P. H. Degnan, J. Hu, I. Peter, W. Zhang, E. Ruggiero, J. H. Cho, A. L. Goodman, and R. A. Flavell:Immunoglobulin A coating identifies colitogenic bacteria in inflammatory bowel disease. Cell 2014, 158:1000-1010